FINWIRES · TerminalLIVE
FINWIRES

Citigroup Downgrades Apogee Therapeutics to Neutral From Buy, Price Target is $135

By

Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $119.07, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $132.65, Change: $+42.27, Percent Change: +46.76%

Related Articles

Citigroup Downgrades Apogee Therapeutics to Neutral From Buy, Price Target is $135 | FINWIRES